| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $85.6M | +96.4% |
| SG&A Expense | $61.3M | +110.2% |
| Operating Income | -$146.9M | -102.0% |
| Net Income | -$40.5M | +99.9% |
| EPS (Basic) | -$2.17 | +53.0% |
| EPS (Diluted) | -$2.17 | +53.0% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $85.3M | -70.0% |
| Short-term Investments | $257.0M | — |
| Current Assets | $347.9M | +20.2% |
| Total Assets | $349.1M | +20.4% |
| Current Liabilities | $16.6M | +91.9% |
| Total Liabilities | $17.0M | +96.3% |
| Stockholders' Equity | $332.0M | +18.1% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$109.9M | -126.4% |
| Capital Expenditures | $26K | — |
| Investing Cash Flow | -$255.1M | -3088.4% |
| Financing Cash Flow | $165.9M | -44.2% |
| Free Cash Flow | -$109.9M | -126.4% |